Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013551

— · cohortSQ1

4169256a-b28e-58f1-8fec-1ed33df5e98f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ1
subtype
cohortSQ1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.490
  • G2M_CHECKPOINT+0.480
  • E2F_TARGETS+0.470
  • MYC_TARGETS_V1+0.410
  • TNFA_SIGNALING_VIA_NFKB+0.340
  • UV_RESPONSE_UP+0.340
  • HYPOXIA+0.320
  • MTORC1_SIGNALING+0.310
  • GLYCOLYSIS+0.290
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.270

Top 10 suppressed

  • PROTEIN_SECRETION-0.310
  • ALLOGRAFT_REJECTION-0.300
  • UV_RESPONSE_DN-0.210
  • BILE_ACID_METABOLISM-0.190
  • KRAS_SIGNALING_UP-0.140
  • INTERFERON_ALPHA_RESPONSE-0.120
  • COMPLEMENT-0.110
  • HEME_METABOLISM-0.110
  • INTERFERON_GAMMA_RESPONSE-0.110
  • IL6_JAK_STAT3_SIGNALING-0.090

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
156218_S133
lung-landscapes@6
—cohortSQ10.816
2SRR8518200
breast-umap@18
—E0.815
3TCGA-56-A5DR-01A-11R-A27Q-07
lung-landscapes@6
—cohortSQ10.809
4MNG1082
mng-umap@100
——0.808
5TCGA-22-0944-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.800
6SRR6013532
lung-landscapes@6
—cohortSQ20.786
7SRR8518205
breast-umap@18
—E0.785
8MNG334
mng-umap@100
——0.778
9SRR12475151
colon-landscapes@1
——0.775
10R26
bladder-landscape@3
——0.775

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.490Idelalisib— uncovered
G2M_CHECKPOINT0.480Inavolisib— uncovered
E2F_TARGETS0.470Inavolisib— uncovered
MYC_TARGETS_V10.410Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.340Inavolisib— uncovered
UV_RESPONSE_UP0.340Idelalisib— uncovered
HYPOXIA0.320Idelalisib— uncovered
MTORC1_SIGNALING0.310Inavolisib— uncovered
GLYCOLYSIS0.290Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.270Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.260Idelalisib— uncovered
ANGIOGENESIS0.250Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.240Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.230Remibrutinib— uncovered
P53_PATHWAY0.230Idelalisib— uncovered
SPERMATOGENESIS0.220Inavolisib— uncovered
APICAL_SURFACE0.190Temsirolimus— uncovered
KRAS_SIGNALING_DN0.180Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.170Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.150Idelalisib— uncovered